Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.

Jessica A. Kahn, Robert D. Burk, Kathleen E. Squires, Bill G. Kapogiannis, Bret Rudy, Jiahong Xu, René Gonin, Nancy Liu, Carol Worrell, Craig M. Wilson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The objectives of this study were to describe the prevalence and risk factors for HPV infection among HIV-infected young women receiving their first quadrivalent HPV (HPV-6, -11, -16, and -18) vaccine dose. We recruited 16- to 23-year-old women from 14 sites for an HPV vaccine trial. At the first visit, they completed a questionnaire and were tested for cervicovaginal HPV DNA (41 types) and HPV serology (4 vaccine types). Factors associated with any HPV, type-specific HPV, and high-risk (cancer-associated) HPV infections were identified using univariate and multivariable logistic regression. The mean age of participants (N = 99) was 21.4 years, 30.3% were on antiretroviral therapy, 74.7% were positive for ≥1 HPV DNA type, 53.5% for ≥1 high-risk type, 12.1% for HPV-16, and 5.1% for HPV-18. Most were HPV DNA negative and seronegative for HPV-16 (55.6%) and HPV-18 (73.7%); 45.5% were HPV DNA negative and seronegative for both HPV-16 and -18. Three variables were associated with high-risk HPV DNA in multivariable analysis: non-Hispanic black versus Hispanic ethnicity (adjusted odds ratio [AOR]: 7.06, 95% CI: 1.63 to 30.5), HIV viral load ≥ 400 versus <400 copies/mL (AOR: 3.47, 95% CI: 1.28 to 9.43), and frequency of vaginal sex in the past 90 days (AOR: 5.82, 95% CI: 1.30 to 26.11 for ≥6 vs 0 times). The prevalence of ≥1 HPV type was high in these young women, demonstrating the importance of vaccinating before sexual initiation. However, most women were HPV DNA negative and seronegative for high-risk vaccine-type HPV infection, supporting vaccination of sexually experienced HIV-positive young women.

Original languageEnglish (US)
Pages (from-to)390-399
Number of pages10
JournalJournal of acquired immune deficiency syndromes (1999)
Volume61
Issue number3
StatePublished - 2012
Externally publishedYes

Fingerprint

Vaccination
HIV
Human papillomavirus 18
Human papillomavirus 16
DNA
Papillomavirus Vaccines
Odds Ratio
Vaccines
Human papillomavirus 11
Human papillomavirus 6
Serology
Infection
Viral Load
Hispanic Americans
HIV Infections
Logistic Models
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination. / Kahn, Jessica A.; Burk, Robert D.; Squires, Kathleen E.; Kapogiannis, Bill G.; Rudy, Bret; Xu, Jiahong; Gonin, René; Liu, Nancy; Worrell, Carol; Wilson, Craig M.

In: Journal of acquired immune deficiency syndromes (1999), Vol. 61, No. 3, 2012, p. 390-399.

Research output: Contribution to journalArticle

Kahn, JA, Burk, RD, Squires, KE, Kapogiannis, BG, Rudy, B, Xu, J, Gonin, R, Liu, N, Worrell, C & Wilson, CM 2012, 'Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.', Journal of acquired immune deficiency syndromes (1999), vol. 61, no. 3, pp. 390-399.
Kahn, Jessica A. ; Burk, Robert D. ; Squires, Kathleen E. ; Kapogiannis, Bill G. ; Rudy, Bret ; Xu, Jiahong ; Gonin, René ; Liu, Nancy ; Worrell, Carol ; Wilson, Craig M. / Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination. In: Journal of acquired immune deficiency syndromes (1999). 2012 ; Vol. 61, No. 3. pp. 390-399.
@article{a1027562b1224a8eb4ad19e356276cdd,
title = "Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.",
abstract = "The objectives of this study were to describe the prevalence and risk factors for HPV infection among HIV-infected young women receiving their first quadrivalent HPV (HPV-6, -11, -16, and -18) vaccine dose. We recruited 16- to 23-year-old women from 14 sites for an HPV vaccine trial. At the first visit, they completed a questionnaire and were tested for cervicovaginal HPV DNA (41 types) and HPV serology (4 vaccine types). Factors associated with any HPV, type-specific HPV, and high-risk (cancer-associated) HPV infections were identified using univariate and multivariable logistic regression. The mean age of participants (N = 99) was 21.4 years, 30.3{\%} were on antiretroviral therapy, 74.7{\%} were positive for ≥1 HPV DNA type, 53.5{\%} for ≥1 high-risk type, 12.1{\%} for HPV-16, and 5.1{\%} for HPV-18. Most were HPV DNA negative and seronegative for HPV-16 (55.6{\%}) and HPV-18 (73.7{\%}); 45.5{\%} were HPV DNA negative and seronegative for both HPV-16 and -18. Three variables were associated with high-risk HPV DNA in multivariable analysis: non-Hispanic black versus Hispanic ethnicity (adjusted odds ratio [AOR]: 7.06, 95{\%} CI: 1.63 to 30.5), HIV viral load ≥ 400 versus <400 copies/mL (AOR: 3.47, 95{\%} CI: 1.28 to 9.43), and frequency of vaginal sex in the past 90 days (AOR: 5.82, 95{\%} CI: 1.30 to 26.11 for ≥6 vs 0 times). The prevalence of ≥1 HPV type was high in these young women, demonstrating the importance of vaccinating before sexual initiation. However, most women were HPV DNA negative and seronegative for high-risk vaccine-type HPV infection, supporting vaccination of sexually experienced HIV-positive young women.",
author = "Kahn, {Jessica A.} and Burk, {Robert D.} and Squires, {Kathleen E.} and Kapogiannis, {Bill G.} and Bret Rudy and Jiahong Xu and Ren{\'e} Gonin and Nancy Liu and Carol Worrell and Wilson, {Craig M.}",
year = "2012",
language = "English (US)",
volume = "61",
pages = "390--399",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.

AU - Kahn, Jessica A.

AU - Burk, Robert D.

AU - Squires, Kathleen E.

AU - Kapogiannis, Bill G.

AU - Rudy, Bret

AU - Xu, Jiahong

AU - Gonin, René

AU - Liu, Nancy

AU - Worrell, Carol

AU - Wilson, Craig M.

PY - 2012

Y1 - 2012

N2 - The objectives of this study were to describe the prevalence and risk factors for HPV infection among HIV-infected young women receiving their first quadrivalent HPV (HPV-6, -11, -16, and -18) vaccine dose. We recruited 16- to 23-year-old women from 14 sites for an HPV vaccine trial. At the first visit, they completed a questionnaire and were tested for cervicovaginal HPV DNA (41 types) and HPV serology (4 vaccine types). Factors associated with any HPV, type-specific HPV, and high-risk (cancer-associated) HPV infections were identified using univariate and multivariable logistic regression. The mean age of participants (N = 99) was 21.4 years, 30.3% were on antiretroviral therapy, 74.7% were positive for ≥1 HPV DNA type, 53.5% for ≥1 high-risk type, 12.1% for HPV-16, and 5.1% for HPV-18. Most were HPV DNA negative and seronegative for HPV-16 (55.6%) and HPV-18 (73.7%); 45.5% were HPV DNA negative and seronegative for both HPV-16 and -18. Three variables were associated with high-risk HPV DNA in multivariable analysis: non-Hispanic black versus Hispanic ethnicity (adjusted odds ratio [AOR]: 7.06, 95% CI: 1.63 to 30.5), HIV viral load ≥ 400 versus <400 copies/mL (AOR: 3.47, 95% CI: 1.28 to 9.43), and frequency of vaginal sex in the past 90 days (AOR: 5.82, 95% CI: 1.30 to 26.11 for ≥6 vs 0 times). The prevalence of ≥1 HPV type was high in these young women, demonstrating the importance of vaccinating before sexual initiation. However, most women were HPV DNA negative and seronegative for high-risk vaccine-type HPV infection, supporting vaccination of sexually experienced HIV-positive young women.

AB - The objectives of this study were to describe the prevalence and risk factors for HPV infection among HIV-infected young women receiving their first quadrivalent HPV (HPV-6, -11, -16, and -18) vaccine dose. We recruited 16- to 23-year-old women from 14 sites for an HPV vaccine trial. At the first visit, they completed a questionnaire and were tested for cervicovaginal HPV DNA (41 types) and HPV serology (4 vaccine types). Factors associated with any HPV, type-specific HPV, and high-risk (cancer-associated) HPV infections were identified using univariate and multivariable logistic regression. The mean age of participants (N = 99) was 21.4 years, 30.3% were on antiretroviral therapy, 74.7% were positive for ≥1 HPV DNA type, 53.5% for ≥1 high-risk type, 12.1% for HPV-16, and 5.1% for HPV-18. Most were HPV DNA negative and seronegative for HPV-16 (55.6%) and HPV-18 (73.7%); 45.5% were HPV DNA negative and seronegative for both HPV-16 and -18. Three variables were associated with high-risk HPV DNA in multivariable analysis: non-Hispanic black versus Hispanic ethnicity (adjusted odds ratio [AOR]: 7.06, 95% CI: 1.63 to 30.5), HIV viral load ≥ 400 versus <400 copies/mL (AOR: 3.47, 95% CI: 1.28 to 9.43), and frequency of vaginal sex in the past 90 days (AOR: 5.82, 95% CI: 1.30 to 26.11 for ≥6 vs 0 times). The prevalence of ≥1 HPV type was high in these young women, demonstrating the importance of vaccinating before sexual initiation. However, most women were HPV DNA negative and seronegative for high-risk vaccine-type HPV infection, supporting vaccination of sexually experienced HIV-positive young women.

UR - http://www.scopus.com/inward/record.url?scp=85027952312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027952312&partnerID=8YFLogxK

M3 - Article

C2 - 22820809

AN - SCOPUS:85027952312

VL - 61

SP - 390

EP - 399

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -